Duffy Null: A Breakthrough for Biomarkers in AA Myeloma Patients | Paul Richardson, MD

Duffy Null: A Breakthrough for Biomarkers in AA Myeloma Patients | Paul Richardson, MD

Can AI Help Detect Myeloma Earlier? New Insights | Faith Davies, MD

Can AI Help Detect Myeloma Earlier? New Insights | Faith Davies, MD

Myeloma Treatment At Home? On-body Injector System for Isatuximab | Sikander Ailawadhi, MD

Myeloma Treatment At Home? On-body Injector System for Isatuximab | Sikander Ailawadhi, MD

Using Sequencing to Measure MRD in the Peripheral Blood | Dory Abelman, PhD | #ASH25

Using Sequencing to Measure MRD in the Peripheral Blood | Dory Abelman, PhD | #ASH25

DREAMM-8 Study- Blenrep in Myeloma | Paul Richardson, MD

DREAMM-8 Study- Blenrep in Myeloma | Paul Richardson, MD

Is Earlier CAR-T the Key to Longer Myeloma Control? | Samir Parekh, MBB

Is Earlier CAR-T the Key to Longer Myeloma Control? | Samir Parekh, MBB

Relapsed & Refractory Myeloma: What’s Changing and What’s Next Rahul Banerjee, MD, FACP

Relapsed & Refractory Myeloma: What’s Changing and What’s Next Rahul Banerjee, MD, FACP

Revolutionizing Myeloma Treatment: BCMA/CD19 Dual CAR-T Explained | Shambavi Richard, MD

Revolutionizing Myeloma Treatment: BCMA/CD19 Dual CAR-T Explained | Shambavi Richard, MD

STOMP Trial - Selinexor + Mezigdomide + Dex in Relapsed Myeloma | Paul Richardson, MD

STOMP Trial - Selinexor + Mezigdomide + Dex in Relapsed Myeloma | Paul Richardson, MD

LimiTEC: Limited-Duration Teclistamab Results | Beatrice Razzo, MD & Cindy Chmielewski

LimiTEC: Limited-Duration Teclistamab Results | Beatrice Razzo, MD & Cindy Chmielewski

Ibrutinib + Venetoclax (I+V) for CLL: Findings from CAPTIVATE & GLOW | Paolo Ghia, MD, PhD

Ibrutinib + Venetoclax (I+V) for CLL: Findings from CAPTIVATE & GLOW | Paolo Ghia, MD, PhD